A Phase III, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of Intramuscular TAK-816 in Healthy Infants
Phase of Trial: Phase III
Latest Information Update: 08 Oct 2018
Price : $35 *
At a glance
- Drugs TAK 816 (Primary)
- Indications Haemophilus infections
- Focus Adverse reactions; Registrational
- Sponsors Takeda
- 20 Apr 2018 Results published in the Vaccine
- 16 Jun 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 23 Apr 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.